Randomised, double-blind, placebo-controlled, parallel-group, multi-centre, phase III trial to investigate the efficacy, safety and tolerability of Naloxone HCl PR Tablets in patients with opioid induced constipation

Trial Profile

Randomised, double-blind, placebo-controlled, parallel-group, multi-centre, phase III trial to investigate the efficacy, safety and tolerability of Naloxone HCl PR Tablets in patients with opioid induced constipation

Recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Sep 2017

At a glance

  • Drugs Naloxone (Primary)
  • Indications Constipation
  • Focus Registrational; Therapeutic Use
  • Acronyms NAXOS
  • Sponsors Develco Pharma Schweiz
  • Most Recent Events

    • 11 Jun 2017 Status changed from planning to recruiting.
    • 08 Mar 2016 New trial record
    • 25 Feb 2016 According to a Algobate media release, the results of this phase III study are anticipated in second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top